bluuebunny/crossref_metadata_2025 huggingface dataset:
Figures S1-S10 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Authors: Wang Zixing , Kim Tae Beom , Peng Bo , Karam Jose , Creighton Chad , Joon Aron , Kawakami Fumi , Trevisan Patricia , Jonasch Eric , Chow Chi-Wan , Canales Jaime Rodriguez , Tamboli Pheroze , Tannir Nizar , Wood Christopher , Monzon Federico , Baggerly Keith , Varella-Garcia Marileila , Czerniak Bogdan , Wistuba Ignacio , Mills Gordon , Shaw Kenna , Chen Ken , Sircar Kanishka
Published: April 2023

Figure S1. Biphasic histologic components of sarcomatoid renal cell carcinoma. The macrodissected paired epithelioid or carcinomatous (E) and spindled or sarcomatoid (S) components of clear cell RCC (upper panel), Papillary RCC (middle panel), and chromophobe RCC (lower panel). H&E stain, scale bar 200 ï�­m. Figure S2. Sarcomatoid ccRCC shows fewer VHL deletions. (A) Clear cell RCC (H&E stain, scale bar 100 Âµm) with (B) Fluorescence in situ hybridization (FISH) image showing paired CEN3q signals (green) and a single VHL signal (red). (C) Sarcomatoid ccRCC (H&E stain, scale bar 100 Âµm) with (D) FISH image showing balanced CEN3q (green) and VHL (red) signals. (E) Box plot showing significantly higher VHL/3q ratios associated with sarcomatoid histology, P<0.008. Figure S3: The smooth scatter plot of signal B versus signal A. Figure S4a: 3p21 and 3p21.1 copy number versus chromosome position. Figure S4b: 3p25 copy number versus chromosome position. Figure S5: Kernel density plots. Each sample per row; left three columns: 3p21; middle three columns: 2q37; and right three columns: 1p1. Figure S6a: Example of more than one peak in the summed signal. Figure S6b: Example of 4 peaks in signals A and B. Figure S7: Density plots of TCGA samples with copy-neutral LOH. Figure S8. VHL and PBRM1 show fewer 2-hit inactivation in sarcomatoid ccRCC. Sarcomatoid ccRCC and ccRCC cases shown in terms of the inactivating "hits" on 3p21-25 genes (VHL, PBRM1, SETD2, BAP1) consisting of mutations or methylation (mutually exclusive for VHL) and deletions. Figure S9. Top activated and inhibited pathways of sarcomatoid samples. Pathways altered by differentially expressed genes between non-sarcomatoid and sarcomatoid samples. The genes selected were differentially expressed in both the TCGA and MD Anderson samples. Figure S10. S- component shows a higher mutational load in sarcomatoid RCC. The total number of non-synonymous mutations in the E- and S- components of sarcomatoid RCC, across all parent RCC subtypes (A) and in clear cell RCC (B).
Supplementary table and Figure legends from FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer
Authors: Weng Wenhao , Okugawa Yoshinaga , Toden Shusuke , Toiyama Yuji , Kusunoki Masato , Goel Ajay
Published: April 2023

Supplementary figures and Table legends
supplemental figure legend from Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Authors: Singhi Aatur D. , Liu Ta-Chiang , Roncaioli Justin L. , Cao Dengfeng , Zeh Herbert J. , Zureikat Amer H. , Tsung Allan , Marsh J. Wallis , Lee Kenneth K. , Hogg Melissa E. , Bahary Nathan , Brand Randall E. , McGrath Kevin M. , Slivka Adam , Cressman Kristi L. , Fuhrer Kimberly , O'Sullivan Roderick J.
Published: April 2023

supplemental figure legend
Supplementary Figures 1-8 from FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer
Authors: Weng Wenhao , Okugawa Yoshinaga , Toden Shusuke , Toiyama Yuji , Kusunoki Masato , Goel Ajay
Published: April 2023

Supplementary Figure 1: The siRNA knockdown efficiency of FOXM1 and FOXQ1 in CRC cells; Supplementary Figure-2: Down-regulation of FOXM1 and FOXQ1 inhibited migration in CRC cell lines; Supplementary Figure-3:Down-regulation of FOXM1 and FOXQ1 inhibited invasion in CRC cell lines; Supplementary Figure-4: MiR-342 directly targets 3'-UTR of FOXM1 and FOXQ1 in HT-29 CRC cells; Supplementary Figure-5: MiR-342 overexpression inhibited cell migration and invasion in SW480 CRC cells; Supplementary Figure 6: Inhibition of miR-342 promotes cell migration and invasion in SW480 CRC cells; Supplementary Figure 7: MiR-342 inhibited cell migration and invasion in HT-29 CRC cells; Supplementary Figure-8: MiR-342 overexpression resulted in down-regulation of FOXM1 and FOXQ1 expression in xenograft tissues.
Supplementary Figure S2 from Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Authors: Singhi Aatur D. , Liu Ta-Chiang , Roncaioli Justin L. , Cao Dengfeng , Zeh Herbert J. , Zureikat Amer H. , Tsung Allan , Marsh J. Wallis , Lee Kenneth K. , Hogg Melissa E. , Bahary Nathan , Brand Randall E. , McGrath Kevin M. , Slivka Adam , Cressman Kristi L. , Fuhrer Kimberly , O'Sullivan Roderick J.
Published: April 2023

Kaplan-Meier curves comparing the cumulative probability of disease-specific survival (DSS) after surgical resection among PanNET patients that developed metastatic disease. No differences in patient DSS rates were detected with respect to ALT (A) and DAXX/ATRX protein expression (B).
Supplementary figure 4 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

PDAC cells matrix adhesions were affect by HPSC supernatant of 24 hour's collection.
Supplemental Material from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Supplemental material
Supplementary figure 3 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Lumican secretion associated with cell matrix migration.
Supplemental Figure 2 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Lack of correlation between Src activity in PBMCs and hepatic tumors. For the patients in the expansion cohort, the change in the expression of pSrc and total Src was not correlated with a change in the phosphorlyation of the Src substrate paxillin. Patients with no change or a decrease in the expression of pSrc or Src from baseline to C2D8 were included in the "no increase" category.
Supplemental Figure 1 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Validation of peripheral blood mononuclear cells as a biomarker of Src inhibition. Freshly collected peripheral blood mononuclear cells from a healthy volunteer were treated ex-vivo with dasatinib 300 nM or hydrogen peroxide 0.05 mM. The peripheral blood mononuclear cell lysates were generated and immunoblotted for phosphoFAK [Y861] and phophopaxillin [Y118].
Table S1 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Authors: Tuxen Ida Viller , Rohrberg Kristoffer Staal , Oestrup Olga , Ahlborn Lise Barlebo , Schmidt Ane Yde , Spanggaard Iben , Hasselby Jane P. , Santoni-Rugiu Eric , Yde Christina Westmose , Mau-Sørensen Morten , Nielsen Finn Cilius , Lassen Ulrik
Published: April 2023

Examples
Supplementary Figure S3 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary Figure S3: Alterations in Protein Expression Associated with D+T Response in Group I PDX lines.
Figure S2 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Authors: Tuxen Ida Viller , Rohrberg Kristoffer Staal , Oestrup Olga , Ahlborn Lise Barlebo , Schmidt Ane Yde , Spanggaard Iben , Hasselby Jane P. , Santoni-Rugiu Eric , Yde Christina Westmose , Mau-Sørensen Morten , Nielsen Finn Cilius , Lassen Ulrik
Published: April 2023

Kaplan-Meier PFS
Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary FigureS2: Response to KRT-232.
Supplementary Figure S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary Figure S1A: Validation of PDX tumors: Short Tandem Repeat (STR) Analysis
Supplementary Tables and Figure from Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Authors: Janku Filip , Zhang Shile , Waters Jill , Liu Li , Huang Helen J. , Subbiah Vivek , Hong David S. , Karp Daniel D. , Fu Siqing , Cai Xuyu , Ramzanali Nishma M. , Madwani Kiran , Cabrilo Goran , Andrews Debra L. , Zhao Yue , Javle Milind , Kopetz E. Scott , Luthra Rajyalakshmi , Kim Hyunsung J. , Gnerre Sante , Satya Ravi Vijaya , Chuang Han-Yu , Kruglyak Kristina M. , Toung Jonathan , Zhao Chen , Shen Richard , Heymach John V. , Meric-Bernstam Funda , Mills Gordon B. , Fan Jian-Bing , Salathia Neeraj S.
Published: April 2023

Supplementary Tables and Figure
Supplementary File 2 from Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Authors: Janku Filip , Zhang Shile , Waters Jill , Liu Li , Huang Helen J. , Subbiah Vivek , Hong David S. , Karp Daniel D. , Fu Siqing , Cai Xuyu , Ramzanali Nishma M. , Madwani Kiran , Cabrilo Goran , Andrews Debra L. , Zhao Yue , Javle Milind , Kopetz E. Scott , Luthra Rajyalakshmi , Kim Hyunsung J. , Gnerre Sante , Satya Ravi Vijaya , Chuang Han-Yu , Kruglyak Kristina M. , Toung Jonathan , Zhao Chen , Shen Richard , Heymach John V. , Meric-Bernstam Funda , Mills Gordon B. , Fan Jian-Bing , Salathia Neeraj S.
Published: April 2023

Supplementary File 2
Supplementary File 1 from Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Authors: Janku Filip , Zhang Shile , Waters Jill , Liu Li , Huang Helen J. , Subbiah Vivek , Hong David S. , Karp Daniel D. , Fu Siqing , Cai Xuyu , Ramzanali Nishma M. , Madwani Kiran , Cabrilo Goran , Andrews Debra L. , Zhao Yue , Javle Milind , Kopetz E. Scott , Luthra Rajyalakshmi , Kim Hyunsung J. , Gnerre Sante , Satya Ravi Vijaya , Chuang Han-Yu , Kruglyak Kristina M. , Toung Jonathan , Zhao Chen , Shen Richard , Heymach John V. , Meric-Bernstam Funda , Mills Gordon B. , Fan Jian-Bing , Salathia Neeraj S.
Published: April 2023

Supplementary File 1
Supplemental Figure 5 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Everolimus Inhibited mTOR Activity as Assessed by pS6 Expression without Significant Correlation with Clinical Activity
Segmentation and quantitation pipeline for image analysis from Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer
Authors: Cornelison Robert , Dobbin Zachary C. , Katre Ashwini A. , Jeong Dae Hoon , Zhang Yinfeng , Chen Dongquan , Petrova Yuliya , Llaneza Danielle C. , Steg Adam D. , Parsons Laura , Schneider David A. , Landen Charles N.
Published: April 2023

Explanation and example analysis pipeline used to quantitate changes in cell size and other parameters. Supplemental Figure 1: (A) Sample images of immunofluorescence of F-actin (red) and DAPI (blue) before and after IC50treatment with CX-5461. Images were taken at random at 200x magnification. Thresholding was performed to identify DAPI stained nuclei using the Mixture of Gaussian (MoG) technique to bin pixels into foreground and background classes. Cytoplasm, marked by F-actin, was segmented using the watershed technique after Sobel transformation followed by Otsu thresholding. All image segmentation and quantitation was performed by CellProfiler. (B) Summary quantitation in representative images of changes to segmented cells' parameters before and after treatment.
Supplemental Figure 4 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Everolimus and Cisplatin Modulation of p73 and p63 Expression In Vivo.
Supplemental Figure 2 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Analysis of Disease-Free Survival across TNBC Subtypes
Supplemental Figure 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Alterations in the PI3K/AKT/mTOR Pathway are not Enriched in Clinical Responders
Figure S2 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Authors: Enblad Gunilla , Karlsson Hannah , Gammelgård Gustav , Wenthe Jessica , Lövgren Tanja , Amini Rose Marie , Wikstrom Kristina I. , Essand Magnus , Savoldo Barbara , Hallböök Helene , Höglund Martin , Dotti Gianpietro , Brenner Malcolm K. , Hagberg Hans , Loskog Angelica
Published: April 2023

Patient plasma prior to CAR treatment (pre) and at three time points post CAR infusion was analyzed by Proseek multiplex proteomics
Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Authors: Vandekerkhove Gillian , Todenhöfer Tilman , Annala Matti , Struss Werner J. , Wong Amanda , Beja Kevin , Ritch Elie , Brahmbhatt Sonal , Volik Stanislav V. , Hennenlotter Jörg , Nykter Matti , Chi Kim N. , North Scott , Stenzl Arnulf , Collins Colin C. , Eigl Bernhard J. , Black Peter C. , Wyatt Alexander W.
Published: April 2023

Methods for blood processing and DNA isolation.
Figure S1 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Authors: Enblad Gunilla , Karlsson Hannah , Gammelgård Gustav , Wenthe Jessica , Lövgren Tanja , Amini Rose Marie , Wikstrom Kristina I. , Essand Magnus , Savoldo Barbara , Hallböök Helene , Höglund Martin , Dotti Gianpietro , Brenner Malcolm K. , Hagberg Hans , Loskog Angelica
Published: April 2023

Manufactured CAR batches were analyzed for the presence of CAR T cells and phenotyped for different markers as indicated in the Figure
Supplementary Table S3 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Table S3 gives an overview of the detected class 3, 4 and 5 variants in the final cohort.
Supplementary Table S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Table S2 shows the clinicopathological characteristics of the homologous recombination intermediate cases.
Supplementary Table S1 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Table S1 shows the clinicopathological characteristics of the cases included in final analysis.
Supplementary Information from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Authors: Dolstra Harry , Roeven Mieke W.H. , Spanholtz Jan , Hangalapura Basav N. , Tordoir Marleen , Maas Frans , Leenders Marij , Bohme Fenna , Kok Nina , Trilsbeek Carel , Paardekooper Jos , van der Waart Anniek B. , Westerweel Peter E. , Snijders Tjeerd J.F. , Cornelissen Jan , Bos Gerard , Pruijt Hans F.M. , de Graaf Aniek O. , van der Reijden Bert A. , Jansen Joop H. , van der Meer Arnold , Huls Gerwin , Cany Jeannette , Preijers Frank , Blijlevens Nicole M.A. , Schaap Nicolaas M.
Published: April 2023

Supplementary materials and methods, Supplementary Tables and Supplementary Figures File Supplementary Table 1. Characteristics of HSPC-NK cell products. Supplementary Table 2. Functional activity of HSPC-NK cell products. Supplementary Table 3. Adverse events associated with Cy/Flu regimen.
Supplementary Figure 3 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Authors: Dolstra Harry , Roeven Mieke W.H. , Spanholtz Jan , Hangalapura Basav N. , Tordoir Marleen , Maas Frans , Leenders Marij , Bohme Fenna , Kok Nina , Trilsbeek Carel , Paardekooper Jos , van der Waart Anniek B. , Westerweel Peter E. , Snijders Tjeerd J.F. , Cornelissen Jan , Bos Gerard , Pruijt Hans F.M. , de Graaf Aniek O. , van der Reijden Bert A. , Jansen Joop H. , van der Meer Arnold , Huls Gerwin , Cany Jeannette , Preijers Frank , Blijlevens Nicole M.A. , Schaap Nicolaas M.
Published: April 2023

Figure S3. HSPC-NK cells mature in vivo.
Supplementary Figure S1 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Figure S1 shows that the Oncoscan and CGH agilent platform yield similar results.
Supplementary Figure 2 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Authors: Dolstra Harry , Roeven Mieke W.H. , Spanholtz Jan , Hangalapura Basav N. , Tordoir Marleen , Maas Frans , Leenders Marij , Bohme Fenna , Kok Nina , Trilsbeek Carel , Paardekooper Jos , van der Waart Anniek B. , Westerweel Peter E. , Snijders Tjeerd J.F. , Cornelissen Jan , Bos Gerard , Pruijt Hans F.M. , de Graaf Aniek O. , van der Reijden Bert A. , Jansen Joop H. , van der Meer Arnold , Huls Gerwin , Cany Jeannette , Preijers Frank , Blijlevens Nicole M.A. , Schaap Nicolaas M.
Published: April 2023

Figure S2. Cy/Flu conditioning induces temporary lymphocytopenia.
Supplementary Figure 1 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Authors: Dolstra Harry , Roeven Mieke W.H. , Spanholtz Jan , Hangalapura Basav N. , Tordoir Marleen , Maas Frans , Leenders Marij , Bohme Fenna , Kok Nina , Trilsbeek Carel , Paardekooper Jos , van der Waart Anniek B. , Westerweel Peter E. , Snijders Tjeerd J.F. , Cornelissen Jan , Bos Gerard , Pruijt Hans F.M. , de Graaf Aniek O. , van der Reijden Bert A. , Jansen Joop H. , van der Meer Arnold , Huls Gerwin , Cany Jeannette , Preijers Frank , Blijlevens Nicole M.A. , Schaap Nicolaas M.
Published: April 2023

Figure S1. Functional activity of HSPC-NK cell products.
Supplemental Methods and Supplemental Figure 1 Legend from Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Authors: Roife David , Dai Bingbing , Kang Ya'an , Rios Perez Mayrim V. , Pratt Michael , Li Xinqun , Fleming Jason B.
Published: April 2023

Supplemental Materials and Methods: Immunohistochemical staining of cleaved caspase 3, statistical analysis of the correlation of LTSA values with patients' progression free survival; Supplemental Figure legend
Supplementary Table 3. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

Donor characteristics, dose and chimerism of NK cells infused.
Supplementary Figure 9 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Survivin protein determination in multiple neuroblastoma lines
Supplementary Figure 4. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

Box and whisker plot showing absolute NK cells per mm3 in samples. NK cells were identified by flow cytometry as CD14 negative, CD56 positive, CD3 negative and percentage of total WBC was computed from flow cytometry results. Absolute WBC count was obtained using a Sysmex{trade mark, serif} KX-21 blood cell analyzer, and final absolute NK count was obtained by multiplying percent NK by absolute WBC. Sample identifiers and associated N are: DONOR (N=10) blood sample drawn at or before time of first NK cell donation; CS1_PRE (N=13), Patient blood drawn prior to first treatment course; CS1_14 (N=9); Patient on day +14 of first treatment course; CS1_21 (N=14), Patient on day +21 of first treatment course; CS2_NK_07 (N=11), Patient on day +7 following NK cell administration in second treatment course; CS2_NK_14 (N=11), Patient on day +14 following NK cell administration in second treatment course; CS3_14 (N=7), Patient on day +14 of third treatment course; CS3_21 (N=9), Patient on day +21 of third treatment course; CS4_NK_07 (N=9), Patient on day +7 following NK cell administration in fourth treatment course; CS4_NK_14 (N=10), Patient on day +14 following NK cell administration in fourth treatment course; CS5_14 (N=3), Patient on day +14 of fifth treatment course; CS5_21 (N=8), Patient on day +21 of fifth treatment course; CS6_PRE (N=1), Patient blood drawn prior to initiation of 6th treatment course; CS6_NK_07 (N=7), Patient on day +7 following NK cell administration in sixth treatment course; CS6_NK_14 (N=7), Patient on day +14 following NK cell administration in sixth treatment course. Central Point (ï�¯) - median; Box - Inner quartiles (25th percentile to 75th percentile) of data; Whiskers - non-outlier min and max data; Outliers (ï,¡) - data points outside of median {plus minus} inner quartile range; Extreme Outliers (*) - data points outside of median {plus minus} 1.5 X inner quartile range.
Supplementary Figure 1. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

Plot of ADCC assay reports comparing 6 lots of hu14.18K322A in comparison to dinutuximab (unituxin). M21 cells, expressing the GD2 cell surface epitope, served as the target cells. Engineered Jurkat cells, with a cell-surface FcyRIIIa (V158) receptor, served as the effector cells. Crosslinking of the two cells by either hu14.18K322A or dinutuximab led to gene transcription through NFAT (nuclear factor of activated T-cells) with subsequent NFAT response element (RE) driving expression of a firefly luciferase reporter protein. The luciferase reporter substrate was converted to a luminescent product and quantified as relative luminescence units (RLU) on a plate reader.
Supplementary Figure 2 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Temsirolimus blocks in vivo tumor growth by suppressing mTOR activity.
Table S4 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Table S4 presents MCPyV-specific T-cell reactivity by patient
Table S2 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Table S2 lists immune-related genes with the greatest fold differences in induction between clinical responders versus non-responders
Table S1 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Table 1 lists the most highly upregulated immune-related genes in the TME post-G100 treatment
Supplementary figure 7 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

Monitoring of cytotoxicity by 7-day treatment with 1nM, 10nM or 100nM of OTS514.
Figure S4 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Figure S4 shows MCPyV-reactive T cells detected post-G100 treatment
Supplementary figure 5 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

Serum levels of OTS514 in mice after oral administration of OTS514.
Supplementary figure 4 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

MTT assay of OTS964 in 11 ovarian cancer cell lines.
Figure S1 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Figure S1 depicts the treatment schema for IT G100 in MCC
Supplementary figure 2 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

Expression of TOPK in each ovarian cancer subtypes and association with prognosis.
Supplementary Data from Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
Authors: Rachner Tilman D. , Kasimir-Bauer Sabine , Göbel Andy , Erdmann Kati , Hoffmann Oliver , Browne Andrew , Wimberger Pauline , Rauner Martina , Hofbauer Lorenz C. , Kimmig Rainer , Bittner Ann-Kathrin
Published: April 2023

1: BCSS according to RANKL/OPG subgroups 2: Multivariate analyses for DTCneg cohort according to RANKL and OPG levels
Supplementary Tables 1-4 from DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression
Authors: Xie Victoria K. , Li Zhiwei , Yan Yongmin , Jia Zhiliang , Zuo Xiangsheng , Ju Zhenlin , Wang Jing , Du Jiawei , Xie Dacheng , Xie Keping , Wei Daoyan
Published: April 2023

Supplementary Table 1. Patients' Characteristics and KLF4 Expression; Supplementary Table 2. Patients' Characteristics and DNMT1 Expression; Table 3. Upregulated microRNAs after DIM Treatment; Table 4. Down-regulated microRNAs after DIM Treatment.
Supplementary Figures 1-8 from DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression
Authors: Xie Victoria K. , Li Zhiwei , Yan Yongmin , Jia Zhiliang , Zuo Xiangsheng , Ju Zhenlin , Wang Jing , Du Jiawei , Xie Dacheng , Xie Keping , Wei Daoyan
Published: April 2023

Supplementary Figure 1. Genetic and epigenetical alterations of KLF4 in pancreatic cancer; Supplementary Figure 2. A demonstration of LCM/ DNA methylation specific PCR analysis of KLF4 promoter methylation; Supplementary Figure 3. Comparison of DNMT1 and KLF4 expressions in pancreatic tissues determined by IHC analysis; Supplementary Figure 4. The effect of DIM treatment on cell cycle progression; Supplementary Figure 5. Spheroid colony formation and tumorigenesis; Supplementary Figure 6. Tumorigenesis assay using orthotopic pancreatic cancer mouse model; Supplementary Figure 7. The effect of DIM treatment on gene expression in pancreatic cancer cells; Supplementary Figure 8. The effects of DIM and miR-152 on gene expression.
Table S1. from Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Authors: Schalper Kurt A. , Carvajal-Hausdorf Daniel , McLaughlin Joseph , Altan Mehmet , Velcheti Vamsidhar , Gaule Patricia , Sanmamed Miguel F. , Chen Lieping , Herbst Roy S. , Rimm David L.
Published: April 2023

Lung cancer cohorts description.
Figure S4. from Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Authors: Schalper Kurt A. , Carvajal-Hausdorf Daniel , McLaughlin Joseph , Altan Mehmet , Velcheti Vamsidhar , Gaule Patricia , Sanmamed Miguel F. , Chen Lieping , Herbst Roy S. , Rimm David L.
Published: April 2023

Modulation of PD-L1, IDO-1 and B7-H4 levels by cytokines in lung adenocarcinoma cells.
Supplemental figure 1 from Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Authors: Bannon Amber E. , Kent Jason , Forquer Isaac , Town Ajia , Klug Lillian R. , McCann Kelly , Beadling Carol , Harismendy Oliver , Sicklick Jason K. , Corless Christopher , Shinde Ujwal , Heinrich Michael C.
Published: April 2023

TIFF file for supplemental figure 1
Figure S2. from Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Authors: Schalper Kurt A. , Carvajal-Hausdorf Daniel , McLaughlin Joseph , Altan Mehmet , Velcheti Vamsidhar , Gaule Patricia , Sanmamed Miguel F. , Chen Lieping , Herbst Roy S. , Rimm David L.
Published: April 2023

Association between PD-L1, IDO-1 and B7-H4 signal and survival in lung cancer.
Figure S1. from Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Authors: Schalper Kurt A. , Carvajal-Hausdorf Daniel , McLaughlin Joseph , Altan Mehmet , Velcheti Vamsidhar , Gaule Patricia , Sanmamed Miguel F. , Chen Lieping , Herbst Roy S. , Rimm David L.
Published: April 2023

Validation of IDO-1 and B7-H4 assays.
Supplementary Figure S1 from Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Authors: Facchinetti Francesco , Loriot Yohann , Kuo Mei-Shiue , Mahjoubi Linda , Lacroix Ludovic , Planchard David , Besse Benjamin , Farace Françoise , Auger Nathalie , Remon Jordi , Scoazec Jean-Yves , André Fabrice , Soria Jean-Charles , Friboulet Luc
Published: April 2023

Supplementary Figure S1. Protein-inhibitor complexes assessed by molecular dynamics studies.
Supplementary Table S1 and S2 from Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities
Authors: Trendowski Matthew R. , El Charif Omar , Dinh Paul C. , Travis Lois B. , Dolan M. Eileen
Published: April 2023

Supplementary Table S1 and S2
Supplementary Table 4 from Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Tetzlaff Michael T. , Curry Jonathan L. , Ning Jing , Sagiv Oded , Kandl Thomas L. , Peng Bo , Bell Diana , Routbort Mark , Hudgens Courtney W. , Ivan Doina , Kim Tae-Boom , Chen Ken , Eterovic Agda Karina , Shaw Kenna , Prieto Victor G. , Yemelyanova Anna , Esmaeli Bita
Published: April 2023

Supplemental Table 4. Fisher's exact test to determine associations between the presence of specific mutations and histopathologic phenotypes in ocular adnexal sebaceous carcinomas.
Supplementary Table 3 from Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Tetzlaff Michael T. , Curry Jonathan L. , Ning Jing , Sagiv Oded , Kandl Thomas L. , Peng Bo , Bell Diana , Routbort Mark , Hudgens Courtney W. , Ivan Doina , Kim Tae-Boom , Chen Ken , Eterovic Agda Karina , Shaw Kenna , Prieto Victor G. , Yemelyanova Anna , Esmaeli Bita
Published: April 2023

Supplemental Table 3. Summary of TP53 and RB1 mutational status, immunohistochemical detection of TP53 and RB and histopathologic features in primary/locally recurrent ocular adnexal (OA) sebaceous carcinomas.
Supplementary Figure Legend from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Authors: Yanagita Masahiko , Redig Amanda J. , Paweletz Cloud P. , Dahlberg Suzanne E. , O'Connell Allison , Feeney Nora , Taibi Myriam , Boucher David , Oxnard Geoffrey R. , Johnson Bruce E. , Costa Daniel B. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplementary Figure Legend
Supplementary Table 2 from Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Tetzlaff Michael T. , Curry Jonathan L. , Ning Jing , Sagiv Oded , Kandl Thomas L. , Peng Bo , Bell Diana , Routbort Mark , Hudgens Courtney W. , Ivan Doina , Kim Tae-Boom , Chen Ken , Eterovic Agda Karina , Shaw Kenna , Prieto Victor G. , Yemelyanova Anna , Esmaeli Bita
Published: April 2023

Supplementary Table 2. Mean per sample coverage information.
Supplemental Figure 1 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Authors: Yanagita Masahiko , Redig Amanda J. , Paweletz Cloud P. , Dahlberg Suzanne E. , O'Connell Allison , Feeney Nora , Taibi Myriam , Boucher David , Oxnard Geoffrey R. , Johnson Bruce E. , Costa Daniel B. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Shown is the schema of study design and enrollment.(30) As noted, the cut-off for data analysis was May 15, 2015.
Supplementary Appendix from A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Authors: Kristeleit Rebecca , Shapiro Geoffrey I. , Burris Howard A. , Oza Amit M. , LoRusso Patricia , Patel Manish R. , Domchek Susan M. , Balmaña Judith , Drew Yvette , Chen Lee-may , Safra Tamar , Montes Ana , Giordano Heidi , Maloney Lara , Goble Sandra , Isaacson Jeff , Xiao Jim , Borrow Jen , Rolfe Lindsey , Shapira-Frommer Ronnie
Published: April 2023

Supplementary data include the following: Figure S1. Rucaparib plasma concentration-time profiles following once daily oral administration Figure S2. Rucaparib plasma concentration-time profiles following twice daily oral administration Figure S3. Observed and predicted relationship between rucaparib dose and exposure at steady state on once-daily (QD) and twice-daily (BID) dosing schedules Figure S4. Radiological response to rucaparib 600 mg BID in a patient with ovarian cancer who had a germline BRCA2 mutation and visceral disease at baseline. Table S1. Summary of pharmacokinetics parameters of rucaparib administered under fasting and fed conditions
Supplementary Data from Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Authors: Kato Shumei , Goodman Aaron , Walavalkar Vighnesh , Barkauskas Donald A. , Sharabi Andrew , Kurzrock Razelle
Published: April 2023

Supplemental Table 1. Patient characteristics of all six individuals with MDM2/4 amplifications who received immunotherapy. Supplemental Table 2. Patient characteristics among patients who received anti-PD-1/PD-L1 (N = 102) Supplemental Table 3. Patients with EGFR alterations and TTF less than 2 months on immunotherapy (N=8 of a total of 10 patients with EGFR alterations). Supplemental Table 4. Patients with DNM3TA alterations and TTF less than 2 months on immunotherapy (N=4 of a total of 5 patients with DNM3TA alterations). Supplemental Figure 1. Evaluation of tumor biopsy at the time of progression (Case #4). Supplemental Figure 2.A. Case #11 Supplemental Figure 2.B. Case #13
Supplementary Figure 5 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Generation of "nurse-like cells" in multiple myeloma.
Supplementary Figure 4 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Pacritinib impairs viability of established nurse-like cells.
Supplementary Materials and Methods, Supplementary Figures 1-7, Supplementary Tables 1-2 from CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma
Authors: Avril Tony , Etcheverry Amandine , Pineau Raphaël , Obacz Joanna , Jegou Gwénaële , Jouan Florence , Le Reste Pierre-Jean , Hatami Masumeh , Colen Rivka R. , Carlson Brett L. , Decker Paul A. , Sarkaria Jann N. , Vauléon Elodie , Chiforeanu Dan Cristian , Clavreul Anne , Mosser Jean , Chevet Eric , Quillien Véronique
Published: April 2023

Figure S1: CD90 mRNA expression on NCI and glioma cell lines, glioma and GBM specimens; Figure S2: CD90 mRNA and protein are expressed on all GBM cells; Figure S3: Expression of adhesion/migration genes in CD90low and CD90high RNS cell lines and EMT associated genes in CD90low and CD90high GBM patients; Figure S4: CD90 affects cell-cell/matrix adhesion of U251 and U87 GBM cell lines; Figure S5: CD90 affects migration of U251, U87 and primary GBM cell lines; Figure S6: CD90 signaling involves SRC and FAK kinases; Figure S7: CD90-dependent migration involves MEK1, Rac1 and JNK signaling molecules; TABLE S1: Patients demographic and clinical characteristics; TABLE S2: Top10 genes up-regulated in CD90low and CD90high GBM patients1.
Supplementary Data from Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Authors: Tallón de Lara Paulino , Cecconi Virginia , Hiltbrunner Stefanie , Yagita Hideo , Friess Martina , Bode Beata , Opitz Isabelle , Vrugt Bart , Weder Walter , Stolzmann Paul , Felley-Bosco Emanuela , Stahel Rolf A. , Tischler Verena , Britschgi Christian , Soldini Davide , van den Broek Maries , Curioni-Fontecedro Alessandra
Published: April 2023

Supplementary data
Supplementary Figure S7 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Example Plot of Prognostic Risk Profile and Cut-Point for EGFR Pathway Genes